[go: up one dir, main page]

EA200600297A1 - Лечение острого воспалительного состояния - Google Patents

Лечение острого воспалительного состояния

Info

Publication number
EA200600297A1
EA200600297A1 EA200600297A EA200600297A EA200600297A1 EA 200600297 A1 EA200600297 A1 EA 200600297A1 EA 200600297 A EA200600297 A EA 200600297A EA 200600297 A EA200600297 A EA 200600297A EA 200600297 A1 EA200600297 A1 EA 200600297A1
Authority
EA
Eurasian Patent Office
Prior art keywords
acute inflammatory
groups
treatment
bodies
phosphate
Prior art date
Application number
EA200600297A
Other languages
English (en)
Inventor
Аркадий Мендел
Энтони Е. Болтон
Original Assignee
Васоджен Айеленд Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Васоджен Айеленд Лимитед filed Critical Васоджен Айеленд Лимитед
Publication of EA200600297A1 publication Critical patent/EA200600297A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01G—COMPOUNDS CONTAINING METALS NOT COVERED BY SUBCLASSES C01D OR C01F
    • C01G19/00—Compounds of tin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82B—NANOSTRUCTURES FORMED BY MANIPULATION OF INDIVIDUAL ATOMS, MOLECULES, OR LIMITED COLLECTIONS OF ATOMS OR MOLECULES AS DISCRETE UNITS; MANUFACTURE OR TREATMENT THEREOF
    • B82B3/00—Manufacture or treatment of nanostructures by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01G—COMPOUNDS CONTAINING METALS NOT COVERED BY SUBCLASSES C01D OR C01F
    • C01G15/00—Compounds of gallium, indium or thallium

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Manufacturing & Machinery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

В этом изобретении предложен способ профилактики или лечения острого воспалительного расстройства, включающий введение пациенту эффективного количества фармацевтически приемлемых телец, несущих эффективное количество фосфатсодержащих групп, которые представлены или могут быть представлены на поверхности указанных телец, причем фосфатсодержащие группы содержат множество глицеролфосфатных групп или групп, поддающихся превращению в такие группы, для ингибирования и/или уменьшения прогрессирования острого воспалительного расстройства, причем указанные тельца имеют размер от примерно 20 нанометров (нм) до 500 микрометров (мкм).
EA200600297A 2003-07-21 2004-07-20 Лечение острого воспалительного состояния EA200600297A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48907103P 2003-07-21 2003-07-21
PCT/CA2004/001053 WO2005007169A2 (en) 2003-07-21 2004-07-20 Liposomes containing phosphate glycerol groups for treating acute inflammatory condition

Publications (1)

Publication Number Publication Date
EA200600297A1 true EA200600297A1 (ru) 2006-08-25

Family

ID=34079469

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200600297A EA200600297A1 (ru) 2003-07-21 2004-07-20 Лечение острого воспалительного состояния

Country Status (15)

Country Link
US (1) US20070238708A1 (ru)
EP (1) EP1658086A2 (ru)
JP (1) JP2006528136A (ru)
KR (1) KR20060037369A (ru)
CN (1) CN1826123A (ru)
AU (1) AU2004257375A1 (ru)
BR (1) BRPI0412882A (ru)
CA (1) CA2533084A1 (ru)
EA (1) EA200600297A1 (ru)
IL (1) IL173068A0 (ru)
MA (1) MA28002A1 (ru)
MX (1) MXPA06000805A (ru)
NO (1) NO20060820L (ru)
WO (1) WO2005007169A2 (ru)
ZA (1) ZA200601458B (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007131329A1 (en) * 2006-05-12 2007-11-22 Vasogen Ireland Limited Treatment of ubiquitin-proteasome system dysfunction related disorders
WO2008121811A2 (en) 2007-03-29 2008-10-09 National Jewish Medical And Research Center Surfactant lipids, compositions thereof, and uses thereof
NZ597419A (en) * 2009-06-03 2014-01-31 John Charles Mayo Formulations for the treatment of deep tissue pain
SG178502A1 (en) * 2009-08-21 2012-03-29 Targeted Delivery Technologies Ltd Vesicular formulations
GB201205642D0 (en) 2012-03-29 2012-05-16 Sequessome Technology Holdings Ltd Vesicular formulations
MX382034B (es) 2015-06-30 2025-03-13 Sequessome Tech Holdings Limited Composiciones multifásicas.

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3346526C2 (de) * 1983-12-22 1986-12-11 A. Nattermann & Cie GmbH, 5000 Köln Pharmazeutisches Präparat zur therapeutischen Behandlung von rheumatischen Erkrankungen
FR2658418B1 (fr) * 1990-02-20 1994-09-02 Synthelabo Compositions pharmaceutiques a base de phospholipides.
WO1995023592A1 (en) * 1994-03-04 1995-09-08 The University Of British Columbia Liposome compositions and methods for the treatment of atherosclerosis
US20020115609A1 (en) * 1997-07-14 2002-08-22 Hayat Onyuksel Materials and methods for making improved micelle compositions
JP3840515B2 (ja) * 1998-11-26 2006-11-01 ブリタニア・ファーマスーティカルズ・リミテッド 界面活性リン脂質を含む抗喘息の組合せ
EP1248628A4 (en) * 1999-12-14 2004-08-04 Sky High Llc PHOSPHOLIPID COMPOSITIONS AS AN INFLAMMATORY INHIBITOR
US20020001614A1 (en) * 2000-02-10 2002-01-03 Kent Jorgensen Lipid-based drug delivery systems containing phospholipase A2 degradable lipid derivatives and the therapeutic uses thereof
US20030040505A1 (en) * 2000-03-31 2003-02-27 The Regents Of The University Of California Synthetic phospholipids to ameliorate atherosclerosis and other inflammatory conditions
CA2368656A1 (en) * 2002-01-21 2003-07-21 Vasogen Ireland Limited Receptor-ligand pairing for anti-inflammatory response
US20040009216A1 (en) * 2002-04-05 2004-01-15 Rodrigueza Wendi V. Compositions and methods for dosing liposomes of certain sizes to treat or prevent disease
CA2499136A1 (en) * 2002-09-16 2004-03-25 Vasogen Ireland Limited Accelerating recovery from trauma
AU2003275842A1 (en) * 2002-10-25 2004-05-13 Vasogen Ireland Limited Cyclooxygenase regulation with pg liposomes
DE10255106A1 (de) * 2002-11-24 2004-06-09 Novosom Ag Liposomale Glucocorticoide

Also Published As

Publication number Publication date
IL173068A0 (en) 2006-06-11
MXPA06000805A (es) 2006-04-18
BRPI0412882A (pt) 2006-10-03
WO2005007169A2 (en) 2005-01-27
CN1826123A (zh) 2006-08-30
US20070238708A1 (en) 2007-10-11
JP2006528136A (ja) 2006-12-14
WO2005007169A3 (en) 2005-09-22
CA2533084A1 (en) 2005-01-27
MA28002A1 (fr) 2006-07-03
NO20060820L (no) 2006-04-10
KR20060037369A (ko) 2006-05-03
ZA200601458B (en) 2007-05-30
AU2004257375A1 (en) 2005-01-27
EP1658086A2 (en) 2006-05-24

Similar Documents

Publication Publication Date Title
BRPI0407375A (pt) Métodos para tratar dor por meio da administração de um antagonista do fator de crescimento neural e u nsaid e composições contendo os mesmos
BRPI0518228B8 (pt) inibidores de cinesina mitótica e uso dos mesmos
NO20050807L (no) Farmasoytiske sammensetninger som innbefatter dekstrometorfan og kinidin for behandling av neurologiske forstyrrelser
EP3530288A3 (en) Methods for treating conditions associated with masp-2 dependent complement activation
CY1110230T1 (el) Αναστολεις γυρασης και χρησεις αυτων
CY1108706T1 (el) Ανοσορυθμιστης
DE60231804D1 (de) Verwendung von hepcidin zur herstellung eines arzneimittels zur behandlung von eisenhomöostase störungen
NO961326D0 (no) Inhibitorer av
DE60042215D1 (de) Zusammensetzungen und verfahren zur behandlung der parkinson-krankheit
WO2006116626A3 (en) Methods and compositions for treating pain
DE60313004D1 (de) Alpha-7-nikotinsäure-rezeptoragonisten und statine in kombination
EA200201276A1 (ru) Производные арилметиламина для использования в качестве ингибиторов триптазы
WO2007120485A3 (en) Methods of treating pain with alkylxanthines and antiepileptics and compositions for use therefor
WO2020154571A8 (en) Compounds and uses thereof
EA200600297A1 (ru) Лечение острого воспалительного состояния
WO2002039994A3 (en) Methods for the treatment and prevention of urinary stone disease
DK1082131T3 (da) Immunoregulator
EA200800092A1 (ru) Композиции в виде наночастиц и с контролируемым высвобождением, включающие арил-гетероциклические соединения
WO2021247921A8 (en) Benzothiazole compounds and uses thereof
WO2022023566A3 (en) Cd-3 antibodies for the treatment of coronavirus
DE60229240D1 (de) Verwendung eines analoges des vitamins d3 zur behandlung des autoimmunen diabetes
NO984160D0 (no) Fremgangsmåte for behandling eller forebyggelse av interstitiell cystitt
WO2006113981A3 (en) Process to obtain dibenzylbutyrolactonic, tetrahydrofuranic lignans and their synthetic and semi-synthetic derivatives, their analgesic and anti-inflammatory activities, topical and/or systemic formulations containing said lignans and their respective therapeutic method
DK1073436T3 (da) Forbedret fremgangsmåde til udryddelse af helicobacter pylori
WO2004028464A3 (en) Methods and compositions for modification of splicing of pre-mrna